- $266.85m
- $495.07m
- $735.75m
Annual income statement for 8x8, fiscal year end - March 31st, USD millions except per share, conversion factor applied.
2022 March 31st | 2023 March 31st | 2024 March 31st | 2025 March 31st | 2026 March 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 638 | 744 | 729 | 715 | 736 |
| Cost of Revenue | |||||
| Gross Profit | 391 | 502 | 504 | 485 | 475 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 792 | 792 | 758 | 712 | 717 |
| Operating Profit | -154 | -47.7 | -29.4 | 2.87 | 18.8 |
| Gain / Loss on Sale of Assets | |||||
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -176 | -70.3 | -64 | -24.1 | 3.53 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -175 | -73.1 | -67.6 | -27.2 | 1.65 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -175 | -73.1 | -67.6 | -27.2 | 1.65 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -175 | -73.1 | -67.6 | -27.2 | 1.65 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -1.48 | -0.709 | -0.488 | -0.198 | 0.012 |